Europe Multiple Sclerosis Market, Patients By (United Kingdom, Germany, France, Italy, Spain) By (Injectables, Infusion, Orals)

1.    Executive Summary

2.    Europe Multiple Sclerosis Patient Numbers (2011 – 2022)
2.1    Patient Number & Forecast

2.2    Disease-Modifying Therapy (DMT) Patient Numbers & Forecast

2.3    By Mode of Administration - Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
2.3.1    Injectables Patients Numbers
2.3.2    Infusions Patients Numbers
2.3.3    Orals Patient Numbers

3.    Europe Multiple Sclerosis Market (2011 – 2022)
3.1    Unmet Market & Forecast

3.2    Market & Forecast

3.3    By Mode of Administration - Market & Forecast
3.3.1    Injectables Market
3.3.2    Infusions Market
3.3.3    Orals Market

4.    Europe Multiple Sclerosis Population Share (2011 – 2022)
4.1    Patient Numbers Share & Forecast

4.2    Disease-Modifying Therapy (DMT) Patient Numbers Share & Forecast

4.3    By Mode of Administration - Patient Numbers Share & Forecast

5.    Europe Multiple Sclerosis Market Share (2011 – 2022)
5.1    By Countries – Unmet Market Share & Forecast

5.2    By Countries – Market Share & Forecast

5.3    By Mode of Administration Market Share & Forecast

6.    United Kingdom
6.1    Multiple Sclerosis Patient Numbers (2011 – 2022)
6.1.1    Patient Number & Forecast
6.1.2    Disease-Modifying Therapy (DMT) Patient Numbers & Forecast

6.2    Multiple Sclerosis Market (2011 – 2022)
6.2.1    Unmet Market & Forecast
6.2.2    Market & Forecast

7.    France
7.1    Multiple Sclerosis Patient Number (2011 – 2022)
7.1.1    Patient Number & Forecast
7.1.2    Disease-Modifying Therapy (DMT) Patient Numbers & Forecast

7.2    Multiple Sclerosis Market (2011 – 2022)
7.2.1    Unmet Market & Forecast
7.2.2    Market & Forecast

8.    Germany
8.1    Multiple Sclerosis Patient Number (2011 – 2022)
8.1.1    Patient Number & Forecast
8.1.2    Disease-Modifying Therapy (DMT) Patient Numbers & Forecast

8.2    Multiple Sclerosis Market (2011 – 2022)
8.2.1    Unmet Market & Forecast
8.2.2    Market & Forecast

9.    Italy
9.1    Multiple Sclerosis Patient Number (2011 – 2022)
9.1.1    Patient Number & Forecast
9.1.2    Disease-Modifying Therapy (DMT) Patient Numbers & Forecast

9.2    Multiple Sclerosis Market (2011 – 2022)
9.2.1    Unmet Market & Forecast
9.2.2    Market & Forecast

10.    Spain
10.1    Multiple Sclerosis Patient Number (2011 – 2022)
10.1.1    Patient Number & Forecast
10.1.2    Disease-Modifying Therapy (DMT) Patient Numbers & Forecast

10.2    Multiple Sclerosis Market (2011 – 2022)
10.2.1    Unmet Market & Forecast
10.2.2    Market & Forecast

11.    Growth Drivers (Due to data confidentiality, growth drivers have not been disclosed in this table of contents)
11.1    Point no. 1

12.    Challenges (Due to data confidentiality, challenges have not been disclosed in this table of contents)
12.1    Point no. 1

12.2    Point no. 2

12.3    Point no. 3

13.    Appendix
 

List of Figures:

Figure 2‑1: Europe - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
Figure 2‑2: Europe – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
Figure 2‑3: Europe - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
Figure 2‑4: Europe – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
Figure 2‑5: Europe – Multiple Sclerosis Injectables Patient Numbers (Thousand), 2011 – 2016
Figure 2‑6: Europe – Forecast for Multiple Sclerosis Injectables Patient Numbers (Thousand), 2017 – 2022
Figure 2‑7: Europe - Multiple Sclerosis Infusions Patient Numbers (Thousand), 2011 – 2016
Figure 2‑8: Europe – Forecast for Multiple Sclerosis Infusions Patient Numbers (Thousand), 2017 – 2022
Figure 2‑9: Europe - Multiple Sclerosis Orals Patient Numbers (Thousand), 2011 – 2016
Figure 2‑10: Europe – Forecast for Multiple Sclerosis Orals Patient Numbers (Thousand), 2017 – 2022

Figure 3‑1: Europe – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 3‑2: Europe – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 3‑3: Europe – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 3‑4: Europe – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022
Figure 3‑5: Europe – Multiple Sclerosis Injectables Market (Million US$), 2011 – 2016
Figure 3‑6: Europe – Forecast for Multiple Sclerosis Injectables Market (Million US$), 2017 – 2022
Figure 3‑7: Europe – Multiple Sclerosis Infusions Market (Million US$), 2011 – 2016
Figure 3‑8: Europe – Forecast for Multiple Sclerosis Infusions Market (Million US$), 2017 – 2022
Figure 3‑9: Europe – Multiple Sclerosis Orals Market (Million US$), 2011 – 2016
Figure 3‑10: Europe – Forecast for Multiple Sclerosis Orals Market (Million US$), 2017 – 2022

Figure 4‑1: Europe - Patient Numbers Share (Percent), 2011 – 2016
Figure 4‑2: Europe – Forecast for Patient Numbers Share (Percent), 2017 – 2022
Figure 4‑3: Europe - Disease-Modifying Therapy (DMT) Patient Numbers Share (Percent), 2011 – 2016
Figure 4‑4: Europe – Forecast for Disease-Modifying Therapy (DMT) Patient Numbers Share (Percent), 2017 – 2022
Figure 4‑5: Europe – Multiple Sclerosis Mode of Administration Patient Numbers Share (Percent), 2011 – 2016
Figure 4‑6: Europe – Forecast for Multiple Sclerosis Mode of Administration Patient Numbers Share (Percent), 2017 – 2022
Figure 4‑7: Europe – Multiple Sclerosis Unmet Market Share (Percent), 2011 – 2016
Figure 4‑8: Europe – Forecast for Multiple Sclerosis Unmet Market Share (Percent), 2017 – 2022
Figure 4‑9: Europe – Multiple Sclerosis Market Share (Percent), 2011 – 2016
Figure 4‑10: Europe – Forecast for Multiple Sclerosis Market Share (Percent), 2017 – 2022
Figure 4‑11: Europe – Multiple Sclerosis Market by Mode of Administration Share (Percent), 2011 – 2016
Figure 4‑12: Europe – Forecast for Multiple Sclerosis Market by Mode of Administration Share (Percent), 2017 – 2022

Figure 5‑1: United Kingdom – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 5‑2: United Kingdom – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 5‑3: United Kingdom – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 5‑4: United Kingdom – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 5‑5: United Kingdom – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 5‑6: United Kingdom – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 5‑7: United Kingdom – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 5‑8: United Kingdom – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022

Figure 6‑1: France – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 6‑2: France – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 6‑3: France – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 6‑4: France – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 6‑5: France – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 6‑6: France – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 6‑7: France – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 6‑8: France – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022

Figure 7‑1: Germany – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 7‑2: Germany – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 7‑3: Germany – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 7‑4: Germany – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 7‑5: Germany – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 7‑6: Germany – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 7‑7: Germany – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 7‑8: Germany – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022

Figure 8‑1: Italy – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 8‑2: Italy – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 8‑3: Italy – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 8‑4: Italy – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 8‑5: Italy – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 8‑6: Italy – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 8‑7: Italy – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 8‑8: Italy – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022

Figure 9‑1: Spain – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 9‑2: Spain – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 9‑3: Spain – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 9‑4: Spain – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 9‑5: Spain – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 9‑6: Spain – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 9‑7: Spain – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 9‑8: Spain – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022

Figure 11‑1: Europe - Number of Neurologists per 100,000 Specialized in MS Vs. Per cent of MS Population Receiving DMDs, 2013

List of Tables

Table 10 1: Europe - Reimbursements for Disease-Modifying Drugs (DMDs), 2013